Another study of RES and CIS combination treatment was conducted on MCF-7 and T47-D (both estrogen receptor-positive cells) and MDA-MB-231 (estrogen receptor-negative cells) [162]. This evidence concerns the gene ESR1 and in situ carcinoma.